Stifel lowered the firm’s price target on Treace Medical (TMCI) to $5 from $6 and keeps a Hold rating on the shares. The company’s Q3 and 2025 guidance update were more complicated than anticipated, as sales did outperform, but management indicated on the call that ta distributor order of roughly $6M made Q3 appear better than the underlying business reality, the analyst tells investors in a research note. The firm noted, however, that CEO John Treace did highlight several factors that support the potential for both more consistent execution and an improved outlook ahead.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical price target lowered to $7.50 from $12 at Lake Street
- Treace Medical price target lowered to $5.85 from $6.50 at UBS
- Treace Medical downgraded to Neutral from Buy at BTIG
- Treace Medical downgraded to Underweight from Neutral at JPMorgan
- Treace Medical Concepts Reports Q3 2025 Financial Results